Drugs / Ulevostinag
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03010176 | Feb 2017 → Apr 2022 | cancer, lymphoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04220866 | Mar 2020 → Sep 2022 | head and neck squamous cell carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ulevostinag | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04220866 ↗ |
| Action | Activate | “the cyclic dinucleotide stimulator of IFN genes (STING) agonist ulevostinag” PMID 40499147 ↗ Aug 2025 |
| Modality | Other / unclassified | “the cyclic dinucleotide stimulator of IFN genes (STING) agonist ulevostinag” PMID 40499147 ↗ Aug 2025 |
| Route | Other | “received intratumoral ulevostinag (±intravenous pembrolizumab)” PMID 40499147 ↗ Aug 2025 |